Social Capital Suvretta Holdings III (Social Capital Suvretta Holdings III) Net Change in Cash : $0.00 Mil (TTM As of Dec. 2021)

View and export this data going back to 2021. Start your Free Trial

What is Social Capital Suvretta Holdings III Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Social Capital Suvretta Holdings III's Net Change in Cash for the six months ended in Dec. 2021 was $0.00 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2021 was $0.00 Mil.

Social Capital Suvretta Holdings III Net Change in Cash Historical Data

The historical data trend for Social Capital Suvretta Holdings III's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Social Capital Suvretta Holdings III Net Change in Cash Chart

Social Capital Suvretta Holdings III Annual Data

Trend

Dec21

Net Change in Cash

Social Capital Suvretta Holdings III Semi-Annual Data
	Dec21
Net Change in Cash	-

Social Capital Suvretta Holdings III Net Change in Cash Calculation

Social Capital Suvretta Holdings III's Net Change in Cash for the fiscal year that ended in Dec. 2021 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	0	+	0	+	0	+	0
	=	0.00

Social Capital Suvretta Holdings III's Net Change in Cash for the quarter that ended in Dec. 2021

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= 0 + 0 + 0 + 0

= 0.00

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2021 was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Social Capital Suvretta Holdings III Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Social Capital Suvretta Holdings III's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Social Capital Suvretta Holdings III (Social Capital Suvretta Holdings III) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Social Capital Suvretta Holdings Corp III (NAS:DNAC) » Definitions » Net Change in Cash

Comparable Companies

PFTA GFGD DNAA IACC HPX VPCB GGAA GOBI OACB BYN GSHN PSTH XAMS:EPIC ASZ CCYC CVII KAHC DWAC IPOF PBAJ

Traded in Other Exchanges

N/A

Address

2850 W. Horizon Ridge Parkway, Suite 200, Henderson, NV, USA, 89052

Website

https://www.socialcapitalsuvrettaholdings.com

Social Capital Suvretta Holdings Corp III is a blank check company.

Executives

Jennifer A. Fox director C/O NUVATION BIO INC., 1500 BROADWAY, SUITE 1401, NEW YORK NY 10036

Sc Pipe Holdings Llc 10 percent owner 506 SANTA CRUZ AVE., SUITE 300, MENLO PARK CA 94025

Tolerantia, Llc 10 percent owner 110 EAST 59TH STREET, SUITE 3300, NEW YORK NY 10022

Jimenez Santos Jose Ignacio director C/O PROKIDNEY CORP., 3929 WESTPOINT BLVD., SUITE G, WINSTON-SALEM NC 27103

Deepak Jain officer: Chief Operating Officer C/O PROKIDNEY CORP., 3929 WESTPOINT BLVD., SUITE G, WINSTON-SALEM NC 27103

Darin J. Weber officer: SVP of Regulatory Development C/O PROKIDNEY CORP., 3929 WESTPOINT BLVD., SUITE G, WINSTON-SALEM NC 27103

Libbie Parker Mckenzie officer: Chief Medical Officer C/O PROKIDNEY CORP., 3929 WESTPOINT BLVD., SUITE G, WINSTON-SALEM NC 27103

James Coulston officer: Chief Financial Officer C/O PROKIDNEY CORP., 3929 WESTPOINT BLVD., SUITE G, WINSTON-SALEM NC 27103

Sc Master Holdings, Llc 10 percent owner 506 SANTA CRUZ AVENUE, SUITE 300, MENLO PARK CA 94025

Alan Lotvin director 55 NOD ROAD, AVON CT 06001

Timothy Bertram director, officer: Chief Executive Officer C/O TENGION, INC., 2900 POTSHOP LANE, SUITE 100, EAST NORRITON PA 19403

Todd C Girolamo officer: Chief Legal Officer 110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920

Uma Sinha director C/O EIDOS THERAPEUTICS, INC., 101 MONTGOMERY STREET, SUITE 2550, SAN FRANCISCO CA 94101

Control Empresarial De Capitales S.a. De C.v. 10 percent owner INSURGENTES SUR #3500, PB, COL. PENA POBRE, DELEGACION TLALPAN, CP, MEXICO D.F. O5 14060

Pablo G. Legorreta director, 10 percent owner 110 E 59TH STREET, SUITE 3300, NEW YORK NY 10022

Social Capital Suvretta Holdings III (Social Capital Suvretta Holdings III) Headlines

From GuruFocus

ProKidney to present at upcoming investor conferences
By GuruFocusNews GuruFocusNews • 05-30-2022

ProKidney highlights key registrational program elements supporting advancement of REACT�
By GuruFocusNews GuruFocusNews • 05-03-2022

ProKidney to present at upcoming investor conferences
By GuruFocusNews GuruFocusNews • 05-20-2022

ProKidney to present at upcoming investor conferences
By GuruFocusNews GuruFocusNews • 07-09-2022

ProKidney Announces Manufacturing Efficiency Initiatives and Supply Chain Streamlining Expected to Reduce REACT� Manufacturing Costs
By PurpleRose PurpleRose • 07-15-2022

Social Capital Suvretta Holdings Corp. III Announces Pricing of Upsized $220,000,000 Initial Public Offering
By Business Wire Business Wire • 06-30-2021

ProKidney Corroborates the Mechanism of Action of REACT� with Cell Marker Analysis in Patients with Diabetic Chronic Kidney Disease
By GuruFocusNews GuruFocusNews • 06-23-2022

ProKidney confirms Phase 3 program for autologous kidney cell therapy REACT�
By GuruFocusNews GuruFocusNews • 04-12-2022

ProKidney Corroborates the Mechanism of Action of REACT� with Cell Marker Analysis in Patients with Diabetic Chronic Kidney Disease
By PurpleRose PurpleRose • 07-13-2022

ProKidney Announces Online Publication of Trial Design for Phase II Multicenter Clinical Trial of REACT� Autologous Cell Therapy for Treatment of Chronic Kidney Disease
By GuruFocusNews GuruFocusNews • 01-27-2022

Jennifer A. Fox	director	C/O NUVATION BIO INC., 1500 BROADWAY, SUITE 1401, NEW YORK NY 10036
Sc Pipe Holdings Llc	10 percent owner	506 SANTA CRUZ AVE., SUITE 300, MENLO PARK CA 94025
Tolerantia, Llc	10 percent owner	110 EAST 59TH STREET, SUITE 3300, NEW YORK NY 10022
Jimenez Santos Jose Ignacio	director	C/O PROKIDNEY CORP., 3929 WESTPOINT BLVD., SUITE G, WINSTON-SALEM NC 27103
Deepak Jain	officer: Chief Operating Officer	C/O PROKIDNEY CORP., 3929 WESTPOINT BLVD., SUITE G, WINSTON-SALEM NC 27103
Darin J. Weber	officer: SVP of Regulatory Development	C/O PROKIDNEY CORP., 3929 WESTPOINT BLVD., SUITE G, WINSTON-SALEM NC 27103
Libbie Parker Mckenzie	officer: Chief Medical Officer	C/O PROKIDNEY CORP., 3929 WESTPOINT BLVD., SUITE G, WINSTON-SALEM NC 27103
James Coulston	officer: Chief Financial Officer	C/O PROKIDNEY CORP., 3929 WESTPOINT BLVD., SUITE G, WINSTON-SALEM NC 27103
Sc Master Holdings, Llc	10 percent owner	506 SANTA CRUZ AVENUE, SUITE 300, MENLO PARK CA 94025
Alan Lotvin	director	55 NOD ROAD, AVON CT 06001
Timothy Bertram	director, officer: Chief Executive Officer	C/O TENGION, INC., 2900 POTSHOP LANE, SUITE 100, EAST NORRITON PA 19403
Todd C Girolamo	officer: Chief Legal Officer	110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920
Uma Sinha	director	C/O EIDOS THERAPEUTICS, INC., 101 MONTGOMERY STREET, SUITE 2550, SAN FRANCISCO CA 94101
Control Empresarial De Capitales S.a. De C.v.	10 percent owner	INSURGENTES SUR #3500, PB, COL. PENA POBRE, DELEGACION TLALPAN, CP, MEXICO D.F. O5 14060
Pablo G. Legorreta	director, 10 percent owner	110 E 59TH STREET, SUITE 3300, NEW YORK NY 10022